<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04251572</url>
  </required_header>
  <id_info>
    <org_study_id>18/0012U</org_study_id>
    <nct_id>NCT04251572</nct_id>
  </id_info>
  <brief_title>HCV Reinfection After DAA Therapy in PWID in Belgium</brief_title>
  <acronym>REINF_HCV</acronym>
  <official_title>Hepatitis C Reinfection After Successful Directly Acting Antiviral Treatment: A Belgian Interventional Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ziekenhuis Oost-Limburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jessa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Algemeen Ziekenhuis Vesalius</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CAD Limburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sint-Trudo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Free Clinic Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ziekenhuis Netwerk Antwerpen (ZNA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinique Saint Joseph, Liège</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Saint Pierre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Algemeen Ziekenhuis Maria Middelares</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to calculate the incidence of HCV reinfection after
      successful DAA treatment among people who have recently injected drugs. The secondary aim is
      to identify factors associated with reinfection in this population.

      Individuals with active injecting drug abuse with a chronic HCV infection who have achieved
      end of treatment response (ETR; defined as non-detectable HCV RNA at end of treatment) to any
      interferon-free DAA combination will be included in this multicenter interventional study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol is an adapted version of the protocol 'Hepatitis C reinfection after successful
      directly acting antiviral treatment: A North-Atlantic multicenter interventional study'. The
      investigators will plan this study so that the data are similar to this protocol and results
      can be compared within this alliance of hepatologists with special interest in care for
      substance users.

      Study schedule: Data collection will be performed according to the study schedule shown in
      Table 1. Following assessment for SVR12, participants will be followed for 2 years at 6
      months' intervals at the discretion of each study site.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of reinfections in people who inject drugs after cure for hepatitis C infection with direct antiviral therapy</measure>
    <time_frame>up to two years</time_frame>
    <description>Number of reinfections with hepatitis C per 100 persons</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>questionnaire to Identify risk factors associated with HCV reinfection</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>questionaire to Identify risk factors associated with HCV reinfection</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatitis C Virus Infection, Response to Therapy of</condition>
  <condition>Drug Use</condition>
  <arm_group>
    <arm_group_label>HCV reinfection after DAA therapy in PWID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis C virus reinfection after directly acting antiviral treatment in persons who inject drugs. DAA therapy is an inclusion criteria, not an intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling</description>
    <arm_group_label>HCV reinfection after DAA therapy in PWID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionaires</intervention_name>
    <description>Included participants will complete a baseline questionnaire at end of treatment (EOT) and a follow-up questionnaire throughout the follow-up period (Table 1). The questionnaires collect information on socio-demographics (age, gender, ethnicity, employment status, education level, housing status, incarceration, medical history and OST), injecting drug use (drugs injected, injection frequency and sharing of needle/syringe, cookers, cotton/filter or water). Details on the received DAA regime including mode of administration (direct observed therapy, pill box, etc.) and self-reported data on treatment adherence will also be recorded.</description>
    <arm_group_label>HCV reinfection after DAA therapy in PWID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Age 18 years or older

          -  Injecting drug use within 6 months before start of treatment

          -  Achieved an ETR following at least eight weeks of DAA treatment

          -  Completed DAA treatment no more than 6 months prior to inclusion

          -  Blood sample drawn within 6 months pre-treatment stored at -70° C

        Exclusion Criteria:

          -  Patients not fulfilling the inclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert Robaeys, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rob Bielen, dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geert Robaeys, prof. dr.</last_name>
    <phone>+32 89 32 15 60</phone>
    <email>geert.robaeys@zol.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rob Bielen, dr.</last_name>
    <phone>+32 89 32 15 60</phone>
    <email>rob.bielen@zol.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Free Clinic Antwerp</name>
      <address>
        <city>Antwerp</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catharina Mathëi, MD</last_name>
      <phone>+32 32 01 12 60</phone>
    </contact>
    <contact_backup>
      <last_name>Maertens Griet, nurse</last_name>
    </contact_backup>
    <investigator>
      <last_name>Catharina Mathëi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerp</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Bourgeois, dr.</last_name>
      <phone>+32 3 217 77 70</phone>
      <email>stefan.bourgeois@zna.be</email>
    </contact>
    <investigator>
      <last_name>Stefan Bourgeois, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Pierre</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Mulkay, prof. dr.</last_name>
      <phone>0032 24115161</phone>
      <email>Jean-Pierre_MULKAY@stpierre-bru.be</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Vanderwaeren, nurse</last_name>
      <email>vanderwaeren.s@projetlama.be</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Pierre Mulkay, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Busschots, dr.</last_name>
      <phone>+32 89 21 20 61</phone>
      <email>dana.busschots@uhasselt.be</email>
    </contact>
    <contact_backup>
      <last_name>Eefje Dercon, nurse</last_name>
      <phone>+32 89 21 20 61</phone>
      <email>eefje.dercon@cadlimburg.be</email>
    </contact_backup>
    <investigator>
      <last_name>Geert Robaeys, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dana Busschots, drs.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eefje Dercon, nurse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Maria-Middelares</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Van Steenkiste, dr.</last_name>
      <phone>+32 9 246 71 00</phone>
      <email>christophe.vansteenkiste@azmmsj.bee</email>
    </contact>
    <investigator>
      <last_name>Christophe Van Steenkiste, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAD Limburg</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Busschots, drs.</last_name>
      <phone>+32 89 21 20 61</phone>
      <email>dana.busschots@uhasselt.be</email>
    </contact>
    <contact_backup>
      <last_name>Eefje Dercon, nurse</last_name>
      <phone>+32 11 27 42 98</phone>
      <email>eefje.dercon@cadlimburg.be</email>
    </contact_backup>
    <investigator>
      <last_name>Rita Verrando, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filip Janssens, dr.</last_name>
      <phone>+32 11 33 76 00</phone>
      <email>filip.janssens@jessazh.be</email>
    </contact>
    <investigator>
      <last_name>Filip Janssens, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHC Saint-Josephe, Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Bastens, prof. dr.</last_name>
      <phone>32 42 24 89 60</phone>
      <email>boris.bastens@chc.be</email>
    </contact>
    <contact_backup>
      <last_name>Annick Deflandre, study nurse</last_name>
    </contact_backup>
    <investigator>
      <last_name>Boris Bastens, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint-Trudo Ziekenhuis</name>
      <address>
        <city>Sint-Truiden</city>
        <zip>3800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>luc Van Den Bergh, dr.</last_name>
      <phone>+32 11 69 96 00</phone>
      <email>luc.vandenbergh@stzh.be</email>
    </contact>
    <investigator>
      <last_name>luc Van Den Bergh, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Vesalius</name>
      <address>
        <city>Tongeren</city>
        <zip>3700</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annelies Posen, dr.</last_name>
      <phone>+32 12 39 70 05</phone>
      <email>annelies.posen@azvesalius.be</email>
    </contact>
    <investigator>
      <last_name>Annelies Posen, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 30, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasselt University</investigator_affiliation>
    <investigator_full_name>Geert Robaeys</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

